Yin‐Ling Xiu

779 citations
23 papers · 626 indexed · h-index 15
Topics
Cancer-related molecular mechanisms research (9 papers)MicroRNA in disease regulation (9 papers)Circular RNAs in diseases (8 papers)
Partner nations
ChinaJapanAustralia

In The Last Decade

Yin‐Ling Xiu

20 papers receiving 619 citations

Peers

Yin‐Ling Xiu
Comparison fields: 5 of 57
  • Molecular Biology 513
  • Cancer Research 427
  • Oncology 69
  • Reproductive Medicine 46
  • Immunology 42
Replace Yang Shao with:
Yang Shao China
Jung Ki Yoo South Korea
Laura Devis Spain
Ross Wanner United States
Bo‐Liang Liu China
Linjuan Xu China
Guoyan Liu China
Shanshan Zhao China
Mitsuyo Yoshida Japan
Yin‐Ling Xiu relative to Yang Shao China Yang Shao's profile →
Citations per field
00.5×10×20×33×
Yang Shao · 1×
Citations per year

Countries citing papers authored by Yin‐Ling Xiu

Since Specialization
Citations

This map shows the geographic impact of Yin‐Ling Xiu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yin‐Ling Xiu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yin‐Ling Xiu more than expected).

Fields of papers citing papers by Yin‐Ling Xiu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yin‐Ling Xiu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yin‐Ling Xiu. The network helps show where Yin‐Ling Xiu may publish in the future.

Co-authorship network of co-authors of Yin‐Ling Xiu

This figure shows the co-authorship network connecting the top 25 collaborators of Yin‐Ling Xiu. A scholar is included among the top collaborators of Yin‐Ling Xiu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yin‐Ling Xiu. Yin‐Ling Xiu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
#WorkIndexed citations
1 2
2 0
3 1
4 1
5 0
6 0
7 18
8
Relationship between transmembrane serine protease expression and prognosis of esophageal squamous cell carcinoma.
4
9 28
10 64
11 56
12 35
13 58
14 30
15 78
16 16
17 33
18 34
19 3
20 27

About Yin‐Ling Xiu

Yin‐Ling Xiu is a scholar working on Cancer Research, Reproductive Medicine and Molecular Biology, having authored 23 papers that have together received 626 indexed citations. Recurring topics across this work include Cancer-related molecular mechanisms research (9 papers), MicroRNA in disease regulation (9 papers) and Circular RNAs in diseases (8 papers). The work is most often cited by research in Cancer Research (427 citations), Molecular Biology (513 citations) and Reproductive Medicine (46 citations). Yin‐Ling Xiu has collaborated with scholars based in China, Japan and Australia. Frequent co-authors include Yang Zhao, Kaixuan Sun, Xi Chen, Shuo Chen, Zhi‐Hong Zong, Shuo Chen, Xiaona Meng, Jingyi Jiang, Jing Yan and Xiu‐Bo Sang. Their work appears in journals such as PLoS ONE, International Journal of Molecular Sciences and Molecular Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026